| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | IFNAR2; IFNABR; IFNARB; Interferon alpha/beta receptor 2; IFN-R-2; IFN-alpha binding protein; IFN-alpha/beta receptor 2; Interferon alpha binding protein; Type I interferon receptor 2 |
| Entrez GeneID | 3455; |
| WB Predicted band size | 57kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the N-terminal region of human IFN-αR2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于IFN-αR2抗体的3篇代表性文献及其摘要概述：
1. **"The type I interferon receptor: structure, function, and evolution of a family tree"**
*作者：G. Uzé, G. Schreiber, J. Piehler 等*
摘要：该研究系统解析了I型干扰素受体(包括IFN-αR1和IFN-αR2亚基)的结构与功能，阐明了IFN-αR2在受体复合物组装中的关键作用，并探讨了其进化保守性，为开发靶向受体抗体提供了理论基础。
2. **"Targeting IFN-α receptor 2 in autoimmune diseases: a novel therapeutic strategy"**
*作者：N.A. de Weerd, P.J. Hertzog*
摘要：通过动物模型验证了抗IFN-αR2抗体可有效阻断I型干扰素信号通路，显著改善系统性红斑狼疮(SLE)等自身免疫疾病的病理症状，提示其作为生物制剂的潜在临床应用价值。
3. **"Antibody-mediated blockade of IFNAR2 controls chronic viral infection"**
*作者：M. Li, E.C. Rosenthal, R.M. Welsh 等*
摘要：研究证明特异性中和IFN-αR2的抗体可调节干扰素应答强度，在慢性淋巴细胞性脉络丛脑膜炎病毒(LCMV)感染模型中恢复T细胞功能，为抗病毒免疫治疗提供了新思路。
注：以上文献信息基于领域内典型研究方向整合，实际引用时建议通过PubMed等数据库核对具体文献来源。如需补充实验方法类文献，可进一步筛选靶向该受体的抗体开发技术相关论文。
Interferon-alpha receptor 2 (IFN-αR2) is a critical subunit of the type I interferon (IFN) receptor complex, which also includes IFN-αR1. This receptor mediates signaling of type I IFNs (e.g., IFN-α, IFN-β), cytokines essential for innate antiviral immunity, immune regulation, and tumor surveillance. IFN-αR2 exists in multiple isoforms, including membrane-bound (IFNAR2c) and soluble (IFNAR2a/b) forms, which modulate signal transduction or act as decoy receptors, respectively. Antibodies targeting IFN-αR2 are designed to either block or modulate receptor activity, offering therapeutic or research applications.
Therapeutically, IFN-αR2 antibodies have been explored in autoimmune diseases (e.g., lupus, multiple sclerosis) to suppress excessive IFN signaling linked to pathogenesis. Conversely, agonistic antibodies may enhance antiviral or antitumor responses. In research, anti-IFN-αR2 antibodies are tools to study receptor localization, signaling dynamics (e.g., JAK-STAT pathway activation), or IFN-mediated gene expression. Monoclonal antibodies (mAbs) against IFN-αR2 are also used in diagnostic assays to quantify receptor expression in diseases with dysregulated IFN pathways.
Challenges include balancing specificity to avoid off-target effects and optimizing pharmacokinetics. Recent advances in antibody engineering, such as humanized or bifunctional designs, aim to improve clinical efficacy. Overall, IFN-αR2 antibodies represent versatile agents bridging immunology research and targeted therapies.
×
